Cargando…

Multiple mutations in the EGFR gene in lung cancer is rare but should not be forgettable

Detalles Bibliográficos
Autores principales:	Miyata, Ryo, Hamaji, Masatsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742612/ https://www.ncbi.nlm.nih.gov/pubmed/36519021 http://dx.doi.org/10.21037/tlcr-22-683

Ejemplares similares

Diagnostic and planned salvage pulmonary metastasectomy
por: Hamaji, Masatsugu, et al.
Publicado: (2022)

A ‘forgettable minority’? Psychiatric Institutions and the Intellectually Disabled in Ireland, 1965–84
por: Kilgannon, David
Publicado: (2020)

Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
por: Moriya, Tetsuji, et al.
Publicado: (2021)

Arabidopsis FORGETTER1 mediates stress-induced chromatin memory through nucleosome remodeling
por: Brzezinka, Krzysztof, et al.
Publicado: (2016)

Plombage for Hemoptysis Control in Pulmonary Aspergilloma: Safety and Effectiveness of Forgettable Surgery in High-Risk Patients
por: Giang, Nguyen Truong, et al.
Publicado: (2021)

Indolent stage IVA thymic malignancies managed with multimodality treatments
por: Hamaji, Masatsugu
Publicado: (2020)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Can we cure metastatic EGFR-mutated lung cancer today?
por: Christopoulos, Petros
Publicado: (2023)

Multiple mutations in the EGFR gene in lung cancer: a systematic review
por: Castañeda-González, Juan Pablo, et al.
Publicado: (2022)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?
por: Bieńkowski, Michał, et al.
Publicado: (2022)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation
por: Kawase, Akikazu, et al.
Publicado: (2022)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

EGFR Mutations and Lung Cancer
Publicado: (2005)

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
por: Ikemura, Shinnosuke, et al.
Publicado: (2019)

Unarranged territory in uncommon EGFR mutations
por: Fujii, Hiroyuki, et al.
Publicado: (2022)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Different EGFR gene mutations in two patients with synchronous multiple lung cancers: A case report
por: Sakai, Hiroki, et al.
Publicado: (2017)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer
por: Li, Chunxiang, et al.
Publicado: (2021)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Synchronous Multiple Lung Cancers with Lymph Node Metastasis and Different EGFR Mutations: Intrapulmonary Metastasis or Multiple Primary Lung Cancers?
por: Qu, Rirong, et al.
Publicado: (2021)

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
por: Yanagisawa, Atsushi, et al.
Publicado: (2022)

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
por: Harrison, Peter T., et al.
Publicado: (2020)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

Germline EGFR mutations in lung cancer (Review)
por: Liu, Minghui, et al.
Publicado: (2023)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Attention Should be Drawn to Rare Diseases and Interpretation of Sequence Variants
por: Tang, Bei-Sha
Publicado: (2016)

Why we should care about ultra-rare disease
por: Harari, Sergio
Publicado: (2016)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma
por: Banerjee, Rahul, et al.
Publicado: (2023)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qa3m1ce2malt9ibntgacj9mb7j